Patent · US Active

Use of a Pde 5 inhibitor for treating and preventing hypopigmentary disorders

US8268785B2 · kind B2 · utility

0Cited by

1References

6Claims

0Family size

Assignee

Switch Biotech AG · DE

Inventor

Heidemarie Peuker · Penzberg, DE

Key dates

Filing date	Jul 15, 2005
Grant date	Sep 18, 2012
Priority date	—
Expiry date	May 7, 2027

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P17/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to the use of PDE5 inhibitors, preferably sildenafil or tadalafil, optionally in combination with a further active ingredient, for treating and/or preventing hypopigmentary disorders.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.